These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

294 related items for PubMed ID: 3700342

  • 1. Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.
    Jayaram G, Coyle J, Tune L.
    J Clin Psychiatry; 1986 May; 47(5):247-8. PubMed ID: 3700342
    [Abstract] [Full Text] [Related]

  • 2. Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.
    Brown WA, Silver MA.
    J Clin Psychopharmacol; 1985 Jun; 5(3):143-7. PubMed ID: 3998204
    [Abstract] [Full Text] [Related]

  • 3. Relapse rate and low serum neuroleptic levels in schizophrenics treated with fluphenazine: another view.
    Boza RA, Milanes F, Starkey T, Slater V, Dominguez F.
    J Clin Psychiatry; 1988 Jun; 49(6):245. PubMed ID: 2897960
    [No Abstract] [Full Text] [Related]

  • 4. Serum neuroleptic levels during reduced dose fluphenazine decanoate maintenance therapy.
    Heresco-Levy U, Greenberg D, Lerer B, Javitt DC, Brown WA.
    Isr J Psychiatry Relat Sci; 1997 Jun; 34(4):281-9. PubMed ID: 9409085
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Double-blind comparison of haloperidol decanoate and fluphenazine decanoate effectiveness, side-effects, dosage and serum levels during a six months' treatment for relapse prevention.
    Kissling W, Möller HJ, Walter K, Wittmann B, Krueger R, Trenk D.
    Pharmacopsychiatry; 1985 May; 18(3):240-5. PubMed ID: 4011672
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.
    Midha KK, Hubbard JW, Marder SR, Marshall BD, Van Putten T.
    J Psychiatry Neurosci; 1994 Jul; 19(4):254-64. PubMed ID: 7918346
    [Abstract] [Full Text] [Related]

  • 13. The use of fluphenazine decanoate (Modecate)depot therapy in outpatient schizophrenics-a retrospective study.
    Tan CT, Ong TC, Chee KT.
    Singapore Med J; 1981 Aug; 22(4):214-8. PubMed ID: 7323829
    [No Abstract] [Full Text] [Related]

  • 14. Fluphenazine blood levels and clinical response.
    Harris PQ, Friedman MJ, Cohen BM, Cooper TB.
    Biol Psychiatry; 1982 Oct; 17(10):1123-30. PubMed ID: 7171656
    [Abstract] [Full Text] [Related]

  • 15. A pilot study of "low-dose" fluphenazine decanoate in outpatient schizophrenics [proceedings].
    Kane J, Rifkin A, Quitkin F.
    Psychopharmacol Bull; 1979 Apr; 15(2):78-80. PubMed ID: 373007
    [No Abstract] [Full Text] [Related]

  • 16. A comparative trial of haloperidol decanoate and fluphenazine decanoate in chronic schizophrenic patients.
    Wistedt B.
    Int Clin Psychopharmacol; 1986 Jul; 1 Suppl 1():15-23. PubMed ID: 3549878
    [Abstract] [Full Text] [Related]

  • 17. Serum neuroleptic levels, prolactin levels, and relapse: a two-year study of schizophrenic outpatients.
    Faraone SV, Brown WA, Laughren TP.
    J Clin Psychiatry; 1987 Apr; 48(4):151-4. PubMed ID: 2881923
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. A comparative study of pipothiazine palmitate and fluphenazine decanoate in the maintenance of remission of schizophrenia.
    Leong OK, Wong KE, Tay WK, Gill RC.
    Singapore Med J; 1989 Oct; 30(5):436-40. PubMed ID: 2575796
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.